Kura Oncology Inc. (KURA) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of Kura Oncology Inc. (NASDAQ:KURA) from a sell rating to a hold rating in a research report report published on Wednesday morning.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

Separately, Oppenheimer Holdings Inc. restated an outperform rating and set a $16.00 price objective on shares of Kura Oncology in a report on Tuesday, June 21st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $13.94.

Shares of Kura Oncology (NASDAQ:KURA) opened at 5.60 on Wednesday. The company’s market capitalization is $104.96 million. Kura Oncology has a 12-month low of $2.50 and a 12-month high of $25.00. The firm has a 50-day moving average price of $6.13 and a 200 day moving average price of $4.18.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.02. On average, equities research analysts predict that Kura Oncology will post ($1.58) earnings per share for the current year.

An institutional investor recently bought a new position in Kura Oncology stock. Alethea Capital Management LLC purchased a new position in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned about 0.34% of Kura Oncology at the end of the most recent quarter. Hedge funds and other institutional investors own 43.63% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

5 Day Chart for NASDAQ:KURA

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.